Halozyme Therapeutics (HALO) Jumps: Stock Up 16.6%

Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose almost 17% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the downtrend for the company since Dec 2, as the stock is now down over 2%.

In the last 30-day frame, the company witnessed a negative estimate revision while the Zacks Consensus Estimate remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Halozyme currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Some better-ranked medical stocks include Lannett Company, Inc. (LCI), Jazz Pharmaceuticals plc (JAZZ) and Questcor Pharmaceuticals, Inc. (QCOR). All three companies carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

HALOZYME THERAPEUTICS INC (HALO): Free Stock Analysis Report

LANNETT COMP (LCI): Free Stock Analysis Report

JAZZ PHARMACEUTICALS PLC IRELAND (JAZZ): Free Stock Analysis Report

QUESTCOR PHARMACEUTICALS INC (QCOR): Free Stock Analysis Report


Zacks Investment Research